Candida antigen detection in two premature neonates with disseminated candidiasis

Pediatrics
|November 1, 1984
PubMed

Insights

Candida antigen detection aids in diagnosing systemic candidiasis in premature infants. Monitoring Candida antigen levels helps guide antifungal therapy and confirms recovery in these vulnerable neonates.

Area of Science:

  • Neonatal Medicine
  • Mycology
  • Infectious Diseases

Background:

  • Premature neonates, especially those with low birth weight (<1,200 g), are susceptible to invasive fungal infections.
  • Systemic candidiasis poses a significant risk in neonates receiving broad-spectrum antibiotics and parenteral nutrition.

Observation:

  • Two premature neonates developed systemic candidiasis with clinical manifestations including necrotizing enterocolitis and renal abscesses.
  • Candida albicans was identified in blood, urine, and stool cultures.
  • Elevated levels of the Candida antigen, mannan, were detected in serum during clinical deterioration.

Findings:

  • Systemic antifungal therapy was administered for six weeks.
  • Prolonged antigenemia persisted despite negative follow-up cultures, indicating the utility of antigen monitoring.
  • Antifungal treatment was discontinued once antigen levels normalized, leading to patient recovery.

Implications:

  • Candida antigen detection (mannan) may serve as a valuable biomarker for diagnosing disseminated candidiasis in premature infants.
  • Monitoring antigen levels can inform the duration and efficacy of antifungal treatment.
  • This diagnostic approach can improve patient outcomes and reduce the risk of recurrent fungal infections in high-risk neonates.